The Global Fund maintains flexibilities to ensure the continued flow of quality-assured health products and support countries in their response to COVID-19.
Our operational guidance for Principal Recipients relates to requirements for procuring eligible COVID-19 diagnostic products and managing exceptions on quality assurance testing and sampling. Additionally, we regularly update our list of COVID-19 diagnostic products eligible for procurement with Global Fund financing, in line with our Interim Quality Assurance Requirements.
As presented in the COVID-19 Response Mechanism Technical Information Note, the table below provides an overview of Quality Assurance Requirements for COVID-19 Health Products.
Pharmaceutical products[1] | Diagnostic products | Core Personal Protective Equipment | Medical Devices (exclusive of PPE and condoms) |
---|---|---|---|
Clinical requirements |
|||
Current national, institutional and/or WHO Standard Treatment Guidelines and/or Essential Medicines Lists |
National guidelines and/or conformity with WHO guidance |
National policy/guidelines on infection prevention and control and/or conformity with WHO guidance |
National policy/guidelines on infection prevention and control and/or conformity with WHO guidance |
Quality requirement |
|||
(1) Approved by national regulators; and |
(1) In compliance with all applicable laws and regulations and; (2) Is manufactured at a site that complies with relevant quality management system requirements; and |
(1) Approved by national regulators; and |
For all Classes (A, B, C and D) (1) Approved by national regulators; and |
(2) Approved under the WHO Emergency Use and Listing procedures or under other emergency procedures set up by any Stringent Regulatory Authority as defined under the Global Fund QA Policy for Pharmaceuticals) |
(3) Approved under the WHO Emergency Use and Listing procedures or under other emergency procedures set up by any Stringent Regulatory Authority as defined under the Global Fund QA Policy for Diagnostics) |
(2) Approved by Stringent Regulatory Authorities (Founding Members of the Global Harmonization Task), WHO Prequalification Programme or Expert Review Panel |
If Class C or Class D, then also: (2) Approved by Stringent Regulatory Authorities (Founding Members of the Global Harmonization Task), WHO Prequalification Programme or Expert Review Panel |
[1] - This category is exclusive of essential medicines used for the management of patients with suspected or confirmed COVID-19 diagnosis. Quality assurance requirements for essential medicines are specified in Global Fund’s Quality Assurance Policy for Pharmaceutical Products.
Information related to the quality assurance of health products related to the three diseases is on our Quality Assurance pages.